Can-Fite BioPharma (CANF) News Today $1.48 +0.04 (+2.78%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to SellDecember 15, 2024 | americanbankingnews.com8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugDecember 4, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVNovember 22, 2024 | finanznachrichten.deCan-Fite Biopharma Ltd. ADRNovember 20, 2024 | wsj.comCan-Fite BioPharma Advances in Pancreatic Cancer TrialNovember 13, 2024 | markets.businessinsider.comCan-Fite BioPharma Ltd.: Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11, 2024 | finanznachrichten.deCan-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11, 2024 | globenewswire.comCan-Fite BioPharma Secures Australian Patent for Obesity DrugNovember 4, 2024 | markets.businessinsider.comCan-Fite BioPharma announces an update related to IP status of NamodenosonNovember 4, 2024 | markets.businessinsider.comCan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaNovember 4, 2024 | globenewswire.comCan Fite Biofarma (AMEX:CANF) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comSignificant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonOctober 18, 2024 | globenewswire.comCan-Fite BioPharma Rises 17% After Pancreatic-Cancer Drug Gets Orphan DesignationOctober 9, 2024 | marketwatch.comFDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerOctober 9, 2024 | markets.businessinsider.comFDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic CancerOctober 9, 2024 | globenewswire.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29October 7, 2024 | finance.yahoo.comCan-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthSeptember 16, 2024 | globenewswire.comCan-Fite reports H1 financials, clinical progressAugust 30, 2024 | investing.comIs Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?August 30, 2024 | msn.comCan-Fite BioPharma Ltd.: Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAugust 29, 2024 | finanznachrichten.deCan-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAugust 29, 2024 | globenewswire.comOS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVAugust 9, 2024 | finanznachrichten.deCan-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAugust 8, 2024 | globenewswire.comCan-Fite BioPharma Ltd.: Can-Fite Provides Namodenoson Patent UpdateJuly 29, 2024 | finanznachrichten.deCan-Fite Provides Namodenoson Patent UpdateJuly 29, 2024 | globenewswire.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8July 17, 2024 | globenewswire.comCan-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerJuly 11, 2024 | globenewswire.comCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverJune 24, 2024 | businesswire.comCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyJune 10, 2024 | businesswire.comCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyJune 5, 2024 | businesswire.comIndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart DiseasesMay 29, 2024 | businesswire.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 27, 2024 | finance.yahoo.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 27, 2024 | businesswire.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6May 23, 2024 | finance.yahoo.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6May 23, 2024 | businesswire.comCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyMay 13, 2024 | businesswire.comCan-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMay 10, 2024 | finanznachrichten.deBuy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study OutlookMay 10, 2024 | markets.businessinsider.comCan-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602May 6, 2024 | businesswire.comLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalApril 25, 2024 | businesswire.comCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHApril 15, 2024 | businesswire.comCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsApril 3, 2024 | businesswire.comCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical UpdateMarch 28, 2024 | finanznachrichten.deNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceMarch 11, 2024 | businesswire.comCan-Fite secures Canadian patent for liver disease drugMarch 1, 2024 | investing.comCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaFebruary 28, 2024 | businesswire.comHistorical PricesFebruary 24, 2024 | wsj.comCan-Fite BioPharma Ltd. (CANF)February 22, 2024 | finance.yahoo.comBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical ProspectsFebruary 8, 2024 | markets.businessinsider.comCan Fite Biopharma Ltd (CANF)January 30, 2024 | investing.com Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now CANF Media Mentions By Week CANF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CANF News Sentiment▼0.000.60▲Average Medical News Sentiment CANF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CANF Articles This Week▼11▲CANF Articles Average Week Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies iBio News Pulmatrix News NanoViricides News IN8bio News Cocrystal Pharma News Bullfrog AI News Tenax Therapeutics News Citius Pharmaceuticals News Cognition Therapeutics News Finch Therapeutics Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CANF) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts